| 05/17 | Citigroup Adjusts DexCom's Price Target to $525 From $630, Reiterates Buy Rating | MT |
| 04/29 | Raymond James Adjusts DexCom's Price Target to $486 From $538, Keeps Outperform Rating | MT |
| 04/29 | Morgan Stanley Adjusts Price Target for DexCom to $492 From $514, Maintains Equalweigh.. | MT |
| 04/29 | SVB Leerink Adjusts DexCom's Price Target to $500 From $565, Keeps Outperform Rating | MT |
| 04/29 | Piper Sandler Adjusts DexCom's Price Target to $480 From $725, Reiterates Overweight Ra.. | MT |
| 03/02 | BofA Securities Reinstates DexCom at Buy With $500 Price Target | MT |
| 02/11 | Morgan Stanley Cuts Price Target on DexCom to $514 From $570, Maintains Equalweight Rat.. | MT |
| 02/03 | BTIG Upgrades DexCom to Buy from Neutral, Sets $535 Price Target | MT |
| 01/31 | Oppenheimer Adjusts DexCom's Price Target to $580 From $630, Maintains Outperform Ratin.. | MT |
| 01/19 | Raymond James Adjusts DexCom's Price Target to $538 from $618, Keeps Outperform Rating | MT |
| 01/19 | Wells Fargo Upgrades DexCom to Overweight From Equalweight; Price Target is $575 | MT |
| 01/11 | UBS Adjusts DexCom Price Target to $640 From $660, Maintains Buy Rating | MT |
| 01/07 | Morgan Stanley Lowers DexCom's Price Target to $570 From $576, Maintains Equalweight Ra.. | MT |
| 01/07 | Guggenheim Upgrades DexCom to Buy from Neutral, Sets $580 Price Target | MT |
| 2021 | Berenberg Bank Terminates Coverage on a Number of Companies Due to Analysts' Departures.. | MT |
| 2021 | Oppenheimer Adjusts DexCom PT to $630 From $625, Maintains Outperform Rating | MT |
| 2021 | Piper Sandler Adjusts DexCom's Price Target to $750 From $675, Reiterates Overweight Ra.. | MT |
| 2021 | Raymond James Adjusts DexCom's Price Target to $618 from $515, Keeps Outperform Rating | MT |
| 2021 | Oppenheimer Adjusts DexCom PT to $625 From $525, Maintains Outperform Rating | MT |
| 2021 | Baird Adjusts DexCom's Price Target to $625 From $520, Reiterates Outperform Rating | MT |
| 2021 | SVB Leerink Adjusts DexCom's Price Target to $715 from $500, Keeps Outperform Rating | MT |
| 2021 | UBS Raises DexCom's Price Target to $660 From $610, Reiterates Buy Rating | MT |
| 2021 | Piper Sandler Adjusts DexCom's Price Target to $675 From $650, Reiterates Overweight Ra.. | MT |
| 2021 | Jefferies Adjusts DexCom's Price Target to $655 From $610, Reiterates Buy Rating | MT |
| 2021 | Wells Fargo Adjusts DexCom PT to $575 From $475, Maintains Equal Weight Rating | MT |
| 2021 | Raymond James Adjusts DexCom PT to $618 From $515, Maintains Outperform Rating | MT |
| 2021 | JPMorgan Adjusts DexCom PT to $600 From $500, Maintains Overweight Rating | MT |
| 2021 | Canaccord Genuity Adjusts DexCom PT to $625 From $500, Maintains Buy Rating | MT |
| 2021 | Morgan Stanley Adjusts Price Target on DexCom to $576 From $510, Maintains Equal-Weight.. | MT |
| 2021 | Berenberg Bank Adjusts DexCom PT to $630 From $550 Following Q3 Beat, Maintains Buy Rat.. | MT |
| 2021 | DEXCOM : Guggenheim Downgrades DexCom to Neutral from Buy | MT |
| 2021 | DEXCOM : Piper Sandler Raises Price Target on DexCom to $650 From $550, Maintains Overweig.. | MT |
| 2021 | DEXCOM : Morgan Stanley Adjusts DexCom's Price Target to $510 from $410, Keeps Equalweight.. | MT |
| 2021 | DEXCOM : Oppenheimer Adjusts DexCom PT to $525 From $500 on Q2 Beat & Raised Guidance, Mai.. | MT |
| 2021 | DEXCOM : Raymond James Adjusts DexCom's Price Target to $515 From $466, Keeps Outperform R.. | MT |
| 2021 | DEXCOM : Canaccord Genuity Adjusts DexCom's Price Target to $500 From $455, Reiterates Buy.. | MT |
| 2021 | DEXCOM : UBS Adjusts DexCom's Price Target to $525 From $500, Maintains Buy Rating | MT |
| 2021 | DEXCOM : JPMorgan Adjusts DexCom's Price Target to $500 From $450, Maintains Overweight Ra.. | MT |
| 2021 | DEXCOM : Baird Adjusts DexCom's Price Target to $520 From $460, Keeps Outperform Rating | MT |
| 2021 | DEXCOM : SVB Leerink Adjusts Price Target on DexCom to $500 From $485, Maintains Outperfor.. | MT |
| 2021 | DEXCOM : Piper Sandler Adjusts DexCom's Price Target to $550 From $500, Reiterates Overwei.. | MT |
| 2021 | DEXCOM : Wells Fargo Adjusts DexCom's Price Target to $475 From $380, Keeps Equal-Weight R.. | MT |
| 2021 | DEXCOM : Berenberg Bank Adjusts DexCom's Price Target to $550 From $497 Following Q2 Beat,.. | MT |
| 2021 | DEXCOM : Cowen Analyst Assumes Coverage on Outperform-Rated DexCom, Sets $525 Price Target | MT |
| 2021 | DEXCOM : Oppenheimer Adjusts DexCom PT to $500 From $480, Maintains Outperform Rating | MT |
| 2021 | DEXCOM : Wells Fargo Upgrades DexCom to Equal-Weight From Underweight; Price Target is $38.. | MT |
| 2021 | DEXCOM : Barclays Initiates Coverage on DexCom With Overweight Rating, $500 Price Target | MT |
| 2021 | DEXCOM : Oppenheimer Adjusts DexCom PT to $480 From $450 on Q1 Beat and Raised Guidance, M.. | MT |
| 2021 | DEXCOM : Raymond James Adjusts Price Target on DexCom to $466 From $449, Maintains Outperf.. | MT |
| 2021 | DEXCOM : UBS Adjusts DexCom's Price Target to $500 From $475, Citing Higher 2022 Sales Est.. | MT |
| 2021 | DEXCOM : Citigroup Adjusts DexCom's Price Target to $488 From $480, Maintains Buy Rating | MT |
| 2021 | DEXCOM : Atlantic Equities Starts DexCom at Overweight With $438 Price Target | MT |
| 2021 | DEXCOM : Oppenheimer Adjusts DexCom PT to $450 From $445, Maintains Outperform Rating | MT |
| 2021 | DEXCOM : UBS Adjusts DexCom's Price Target to $475 From $445, Maintains Buy Rating | MT |
| 2021 | DEXCOM : Morgan Stanley Adjusts Price Target on DexCom to $410 From $402, Maintains Equal-.. | MT |
| 2021 | DEXCOM : UBS Raises DexCom to Buy From Neutral, PT to $445 From $410, Citing Pharmacy Shif.. | MT |
| 2020 | DEXCOM : Morgan Stanley Adjusts DexCom PT to $402 From $398, Maintains Equal Weight Rating | MT |
| 2020 | DEXCOM : Canaccord Genuity Adjusts DexCom's Price Target to $435 From $475, Maintains Buy .. | MT |
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report